Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Aiming to be ‘European anchor’ in expansion rounds, Kurma raises €160M toward growth fund

Seeking to maintain bigger stakes in later rounds, Kurma raises growth fund amid turbulent public markets

March 7, 2022 10:05 AM UTC

Kurma Partners believes its new Growth Opportunities fund can fill a niche by investing in maturing European life sciences companies that aren’t yet ready to test the public markets, including biopharmas around the proof-of-concept stage.

Kurma said Monday it had raised €160 million ($173.8 million) in the fund’s first close, with a €250 million target for a final close. The vehicle will complement Kurma’s core series of Biofunds including the current 2020-vintage, €160 million Biofund III, with which it emphasizes company creation...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Kurma Partners